Latest Publications

Featured Article

Blood Journal. 24/07/2019

Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine Si Lun Tam, Judith Trotman, Stephen Opat, Jan A Burger, Gavin Cull, David J Gottlieb, Rosemary Anne Harrup, Patrick Johnston, Paula Marlton, Javier Munoz, John F. Seymour, David R Simpson, Alessandra Tedeschi, Rebecca Elstrom, Yiling Yu, Zhiyu Tang, Lynn Han, Jane Huang, William Novotny, Lai Wang and Andrew W. Roberts

Link to online journal article

PDF Article

---

This trial shows that zanubrutinib, a tablet taken twice daily, is very active in chronic lymphocytic leukaemia. The response rates were very high and the CLL came under good control in nearly all the patients. The good news for patients is that zanubrutinib was well tolerated with very few having to stop the tablets due to side-effects. While longer follow-up is needed, most patients remain on zanubrutinib with their CLL under very good control.

More Publications

• Author reply.
  Source: Dr Chan CheahPublished on 2019-10-12
• Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
  Source: Dr Chan CheahPublished on 2019-10-02
• Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia.
  Source: Dr Chan CheahPublished on 2019-08-22
• Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia.
  Source: Dr David JoskePublished on 2019-08-22
• Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia.
  Source: Dr Dejan RadeskiPublished on 2019-08-22
• Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.
  Source: Dr Carolyn GrovePublished on 2019-08-20
• Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.
  Source: Dr Rebecca HowmanPublished on 2019-08-20
• Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review.
  Source: Dr Chan CheahPublished on 2019-08-01
• Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review.
  Source: Dr Dejan RadeskiPublished on 2019-08-01
• Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
  Source: Dr Gavin CullPublished on 2019-07-26
• Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of ‘real-world’ experience from Western Australia.
  Source: Dr David JoskePublished on 2019-07-16
• Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of ‘real-world’ experience from Western Australia.
  Source: Dr Gavin CullPublished on 2019-07-16
• Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of ‘real-world’ experience from Western Australia.
  Source: Dr Dejan RadeskiPublished on 2019-07-16
• COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
  Source: Dr Chan CheahPublished on 2019-07-10
• COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
  Source: Dr Bradley AugustsonPublished on 2019-07-10

Older posts